← Back

$ Value

$0

Shares

6,638

Price

$0

Filed

Feb 20

Insider

Name

Thakkar Roopal

Title

EVP, R&D and CSO

CIK

0002004979

Roles

Officer

Transaction Details

Transaction Date

2026-02-18

Code

A

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

60,413

Footnotes

Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029.

Filing Info

Accession No.

0002004979-26-000002

Form Type

4

Issuer CIK

0001551152

Thakkar Roopal's History

Date Ticker Type Value
2026-02-27 ABBV F $1.9M
2026-02-18 ABBV A $0
2026-02-18 ABBV A $0
2026-02-18 ABBV A $0
2026-02-18 ABBV A $0
2026-02-18 ABBV A $0

Other Insiders at ABBV (90d)

Insider Bought Sold Last
RAPP EDWARD J 2026-03-31
Alpern Robert J 2026-03-31
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
2026-02-27
Michael Robert A.
CHAIRMAN OF THE BOARD AND CEO
2026-02-27
Michael Robert A.
CHIEF EXECUTIVE OFFICER
2026-02-18
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
2026-02-27
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
2026-02-27
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
2026-02-27
Siatis Perry C
EVP, GC AND SECRETARY
$9.5M 2026-03-02
Quaggin Susan E 2026-03-31
Thakkar Roopal
EVP, R&D and CSO
2026-02-27
Purdue David Ryan
SVP, Controller
$1.2M 2026-03-04
Crum Demetris D
EVP, CHIEF HR OFFICER
2026-02-27